Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/10572Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Tellis, C. C. | en |
| dc.contributor.author | Derdemezis, C. S. | en |
| dc.contributor.author | Elisaf, M. | en |
| dc.contributor.author | Tselepis, A. | en |
| dc.date.accessioned | 2015-11-24T16:57:22Z | - |
| dc.date.available | 2015-11-24T16:57:22Z | - |
| dc.identifier.issn | 0003-3197 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/10572 | - |
| dc.rights | Default Licence | - |
| dc.subject | adiponectin | en |
| dc.subject | ezetimibe | en |
| dc.subject | fenofibrate | en |
| dc.subject | leptin | en |
| dc.subject | rimonabant | en |
| dc.subject | visfatin | en |
| dc.subject | molecular-weight adiponectin | en |
| dc.subject | cardiometabolic risk-factors | en |
| dc.subject | metabolic syndrome | en |
| dc.subject | visfatin levels | en |
| dc.subject | insulin-resistance | en |
| dc.subject | overweight/obese patients | en |
| dc.subject | endocannabinoid system | en |
| dc.subject | micronized fenofibrate | en |
| dc.subject | cardiovascular-disease | en |
| dc.subject | energy-balance | en |
| dc.title | Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | Doi 10.1177/0003319709352488 | - |
| heal.identifier.secondary | <Go to ISI>://000276897300009 | - |
| heal.identifier.secondary | http://ang.sagepub.com/content/61/4/365.full.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | Weight loss and hypolipidemic drugs can improve lipid and adipokine levels. We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia. Overweight/obese patients (n = 60, body mass index = 27-40 kg/m(2)) with mixed dyslipidemia were recruited. Patients received a hypocaloric diet and were randomized to rimonabant 20 mg/d (group R, n = 20), rimonabant 20 mg/d plus fenofibrate 200 mg/d (group RF, n = 20), or rimonabant 20 mg/d plus ezetimibe 10 mg/d (group RE, n = 20). After 3 months, leptin concentration was significantly reduced in all groups (-38%, P < .005; 40%, P < .005; and 44%, P < .001 in the R, RF, and RE groups, respectively). Total adiponectin remained unaltered. Visfatin concentration decreased significantly only in the RE and RF groups (-18% and 38%, respectively; P < .047). Treatment with rimonabant may improve adipokine levels in overweight/obese patients with dyslipidemia. The addition of fenofibrate or ezetimibe may reinforce this effect. | en |
| heal.journalName | Angiology | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Florentin-2010-Effects of Rimonaban.pdf | 157.35 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
